The USPSTF recently updated their cancer screening guidelines, recommending against prostate cancer screening in men older than 75.
Toni Brayer recaps the controversy surrounding the PSA test. With a Democratic-controlled government, a push is going to be made for a comparative effectiveness institute. There is a real possibility that the dogma of “more screening equals better medicine” will be challenged.
Patients are going to face the repercussions of evidence-based medicine, which means the denial of scores of unproven tests that patients are receiving today.
topics: cancer screening, comparative effectiveness
